Alterity Therapeutics Lim... (ATHE)
NASDAQ: ATHE
· Real-Time Price · USD
5.17
-0.06 (-1.15%)
At close: Aug 15, 2025, 3:59 PM
5.20
0.58%
After-hours: Aug 15, 2025, 06:47 PM EDT
Alterity Therapeutics Income Statement
Financials in AUD. Fiscal
year is
July - June.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q2 2022 | Q4 2021 | Q2 2021 |
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Jun 30, 2022 | Dec 31, 2021 | Jun 30, 2021 | Dec 31, 2020 |
Revenue | 4.78M | 5.88M | 6.03M | 5.44M | 5.15M | 5.63M | 7.45M | 8.27M | 7.51M | 7.58M | 6.7M | 2.48M | 1.88M |
Cost of Revenue | 195.88K | 238K | 254.68K | 233.34K | 237.19K | 213.26K | 187.46K | 166.73K | 104.21K | 93.95K | 106.91K | 326.06K | 388.55K |
Gross Profit | 4.59M | 5.64M | 5.77M | 5.21M | 4.91M | 5.42M | 7.26M | 8.11M | 7.41M | 7.49M | 6.59M | 2.16M | 1.49M |
Operating Income | -29.08M | -33.86M | -33.42M | -26.09M | -22.72M | -24.95M | -32.11M | -34.5M | -31.37M | -30.5M | -29.68M | -27.66M | -23.53M |
Interest Income | 150.02K | 268.42K | 268.42K | 123.46K | 123.46K | 16.44K | 17.59K | 13.88K | 13.88K | 16.63K | 22.03K | 23.66K | 23.67K |
Pretax Income | -28.15M | -32.97M | -32.64M | -25.25M | -21.85M | -23.76M | -29.23M | -30.65M | -27.76M | -26.44M | -28.15M | -27.25M | -23.9M |
Net Income | -26.1M | -29.02M | -28.69M | -21.84M | -18.42M | -19.95M | -22.96M | -23.77M | -20.88M | -19.59M | -21.89M | -23.13M | -22.02M |
Selling & General & Admin | 7.41M | 7.84M | 7.21M | 6.75M | 6.51M | 7.36M | 8.78M | 9.87M | 8.76M | 9.18M | 10.53M | 8.84M | 7.23M |
Research & Development | 24.14M | 27.64M | 27.97M | 21.12M | 17.69M | 19.1M | 23.9M | 25.23M | 22.51M | 21.22M | 19.05M | 16.64M | 15.91M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 31.51M | 35.44M | 35.13M | 27.87M | 24.2M | 26.46M | 32.68M | 35.09M | 31.27M | 30.41M | 29.57M | 25.48M | 23.14M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | 328.69K | 178.97K | 10.88K | 22.99K | 32.59K | 32.85K | 57.28K | 65.41K | 58.3K | 17.24K | 26.14K | 41.33K | 94.07K |
Cost & Expenses | 31.74M | 35.72M | 35.43M | 28.1M | 24.44M | 26.67M | 32.87M | 35.26M | 31.37M | 30.5M | 29.68M | 25.8M | 23.53M |
Income Tax Expense | -2.05M | -3.95M | -3.95M | -3.41M | -3.43M | -3.81M | -6.28M | -6.88M | -6.88M | -6.84M | -6.26M | -4.13M | -1.88M |
Shares Outstanding (Basic) | 8.54M | 8.54M | 10.51M | 8M | 4.17M | 4.17M | 4.07M | 4.02M | 4.02M | 4.01M | 4.01M | 3.47M | 2.21M |
Shares Outstanding (Diluted) | 8.86M | 8.86M | 10.51M | 7.99M | 4.17M | 4.17M | 4.07M | 4.07M | 4.02M | 4.01M | 4.01M | 3.47M | 2.21M |
EPS (Basic) | -2.82 | -3.96 | -4.32 | -4.56 | -4.5 | -4.92 | -5.7 | -5.88 | -5.16 | -5.1 | -7.44 | -10.92 | -12.9 |
EPS (Diluted) | -2.82 | -3.96 | -4.32 | -4.56 | -4.5 | -4.92 | -5.7 | -5.88 | -5.16 | -5.1 | -7.44 | -10.92 | -12.9 |
EBITDA | -28.62M | -33.2M | -32.73M | -25.37M | -22M | -23.93M | -29.34M | -30.77M | -27.66M | -26.34M | -28.05M | -27.5M | -24.31M |
EBIT | -28.72M | -33.36M | -32.9M | -25.51M | -22.14M | -24.05M | -29.47M | -30.88M | -27.76M | -26.44M | -28.15M | -27.58M | -24.37M |
Depreciation & Amortization | 98.97K | 164.45K | 165.2K | 143.86K | 144.45K | 120.53K | 134.03K | 113.3K | 104.21K | 93.95K | 106.91K | 86.97K | 104.45K |